Jane Street Group LLC Buys 55,867 Shares of CureVac (NASDAQ:CVAC)

Jane Street Group LLC raised its stake in CureVac (NASDAQ:CVAC) by 239.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 79,247 shares of the company’s stock after buying an additional 55,867 shares during the period. Jane Street Group LLC’s holdings in CureVac were worth $235,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Point72 Asset Management L.P. bought a new stake in shares of CureVac in the 2nd quarter valued at about $8,237,000. China Universal Asset Management Co. Ltd. grew its position in shares of CureVac by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock valued at $127,000 after buying an additional 16,792 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in shares of CureVac by 99.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock valued at $147,000 after buying an additional 21,999 shares during the last quarter. Signaturefd LLC lifted its stake in shares of CureVac by 26.9% in the 3rd quarter. Signaturefd LLC now owns 27,970 shares of the company’s stock valued at $82,000 after purchasing an additional 5,927 shares during the period. Finally, Green Alpha Advisors LLC lifted its stake in shares of CureVac by 41.3% in the 3rd quarter. Green Alpha Advisors LLC now owns 27,319 shares of the company’s stock valued at $80,000 after purchasing an additional 7,979 shares during the period. Institutional investors own 17.26% of the company’s stock.

CureVac Stock Down 0.5 %

Shares of NASDAQ:CVAC opened at $4.21 on Friday. The company has a market capitalization of $942.53 million, a price-to-earnings ratio of 7.65, a P/E/G ratio of 0.24 and a beta of 2.50. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The business’s 50-day moving average is $3.09 and its 200-day moving average is $3.15. CureVac has a 1 year low of $2.21 and a 1 year high of $5.28.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reissued a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research note on Monday, September 16th.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.